PARIS (Reuters) – Healthcare companies Sanofi and partner Regeneron presented on Tuesday more positive data for their Dupixent product.
The companies said new data showed that Dupixent showed a significant histological remission of eosinophilic esophagitis in children 1 to 11 years old. Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly.
(Reporting by Sudip Kar-Gupta; Editing by Christian Schmollinger)